BUSINESS WIRE; Thursday May 28, 7:57 am EST
The study, among the first to compare the effectiveness of selective serotonin re-uptake inhibitor antidepressants like Prozac against psychotherapy, also shows that Prozac did not interact significantly with any HIV medications and produced minimal side effects. Results of the study might lead to better compliance by patients already taking multiple drug therapies, according to Sidney Zisook, M.D., professor of psychiatry with UCSD School of Medicine and lead author of the study.
Major depressive episodes are estimated to be present in 7 to 20 percent of all HIV-positive patients. HIV patients often suffer multiple medical complications and tend to receive a number of potentially toxic medications during the course of their illness.
"They can ill afford to receive yet another medication unless the treatment is safe," said Zisook.
The randomized, double blind, placebo-controlled study examined 47 HIV positive men who were seen in weekly supportive group therapy. The sample consisted of men who had recurrent major depression and whose present episode had been continuing for at least several months. On average, patients had been HIV positive for about three years prior to entry into the study. Twenty-five patients were given up to 60 mg of Prozac during the seven week trial.
Twenty-two patients received a placebo.
Researchers found statistically significant differences favoring group psychotherapy plus Prozac over group psychotherapy plus placebo. Patients treated with Prozac experienced a two-fold improvement in baseline depression rating scales (12.1 for subjects given Prozac vs. 6.6 for subjects given the placebo.) A greater percentage of patients in the Prozac group (64 percent vs. 23 percent) experienced a reduction of at least 50 percent in depression rating scores. Similarly, the percentage of patients who were rated as either very much improved or much improved was higher (64 percent vs. 48 percent) in the Prozac group.
Among patients rated as severely depressed, those treated with psychotherapy plus Prozac appeared to do significantly better than those treated with psychotherapy and placebo. Patients rated as mild to moderately depressed appeared to do equally well whether treated with psychotherapy and Prozac or psychotherapy and placebo.
"As the HIV epidemic continues to spread world wide, more HIV positive men and women with depression can expect to require treatment," said Dr. Zisook. "Patients who are HIV positive and experience depression can and do respond to antidepressant treatment."
Factors that may contribute to the onset of a major depression in patients with HIV include isolation from social supports, occupational disability, alterations in body image, bereavement, loss of friends, debilitation, effects of HIV virus on the brain, and the knowledge of having a terminal illness.
Although patients were taking antiretroviral agents such as AZT, the study was completed before the widespread use of protease inhibitors. No serious drug interactions involving the combination of protease inhibitors and SSRIs have been reported. However, the potential for drug interactions does exist. Since all patients were treated with group psychotherapy, the study is not considered a true placebo study. Several smaller studies have supported the effectiveness of group psychotherapy for treating HIV-associated depression.
Co-authors on the study are Joanna Peterkin, M.D., and Kathleen J. Goggin, Ph.D., both of the New York State Psychiatric Institute and Cornell University Medical College; Paul Sledge, Ph.D., California State University, San Marcos; and J. Hampton Atkinson, M.D. and Igor Grant, M.D., both of UCSD School of Medicine.
The study was supported by the HIV Neurobehavioral Research Center at UCSD School of Medicine and by Eli Lilly and Company [NYSE:LLY - news].
Contact: Chamberlain Communications Group Anat Jacobson (212) 732-6111 or Chamberlain Communications Group Kere Thomas (212) 732-6111
980528
BW980512
Copyright © 1998 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .